Oramed Pharmaceuticals Inc. — Director's Dealing 2014

Apr 2, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2014-03-31

Reporting Person: Berelowitz Michael (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-03-31	Common Stock	M	3334	$4.08	Acquired	3334	Direct
2014-03-31	Common Stock	M	6100	$5.76	Acquired	9434	Direct
2014-03-31	Common Stock	S	9434	$10.50	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-03-31	Stock Option (right to buy)	$4.08	M	3334	Disposed	2022-08-08	Common Stock (3334)	Direct
2014-03-31	Stock Option (right to buy)	$5.76	M	6100	Disposed	2020-07-07	Common Stock (6100)	Direct

Footnotes

F1: The number of shares underlying such Stock Options and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.

F2: This Stock Option vested in equal parts on each of January 1, 2013 and January 1, 2014.

F3: This Stock Option vested in equal parts on each of July 8, 2011, July 8, 2012 and July 8, 2013.